BCMA CAR T approvals (ide-cel 2021; cilta-cel 2022) deliver near-98% response in trials but require specialized centers, creating logistical constraints on access. Across >9 million UC patients, ...
Finding an effective treatment for osteosarcoma, the most common type of bone cancer in children and young adults, has ...
The researchers say that, to their knowledge, this is the first demonstration of programmable, site-specific integration of a ...
Researchers at the University of Colorado Anschutz Medical Campus have successfully developed a supercharged iteration of CAR ...
Consider the case of patient WB, a 79-year-old male with recurrent diffuse large B cell lymphoma. He was referred for chimeric antigen receptor T-cell therapy (CAR-T), a recent game-changer for ...
Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating infectious diseases and ...
Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric antigen receptor on the surface of the patient's T ...
InvestorsHub on MSN
HCW Biologics highlights positive findings for CAR-T therapy manufacturing
HCW Biologics Inc. (NASDAQ:HCWB) announced new research published in Science Advances indicating that its compound HCW9206 ...
Professor Gordon Cook says careful patient selection is needed with CAR-T cell therapy, noting its potential in a disease ...
With promise to slow aging and cure some types of cancer, a new gene therapy presents cost and access hurdles for CT patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results